SCHEMBL6915452

SCHEMBL6915452

CCSc1nsnc1C1=CCCN(CC)C1

nearest known ligand 0.74

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 11/20 0.60
CHRM4 P08173 3/20 0.56
SIGMAR1 Q99720 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL7617389 0.93 CHRM1 (0.53) CHRM1CHRM4
SCHEMBL6906731 0.85 CHRM1 (0.69) CHRM1CHRM4
SCHEMBL6907655 0.85 CHRM1 (0.82) CHRM1CHRM4SIGMAR1
Oxalic Acid SCHEMBL7609554 0.80 CHRM1 (0.61) CHRM1CHRM4
SCHEMBL7469869 0.79 CHRM1 (0.72) CHRM1CHRM4SIGMAR1
SCHEMBL7610951 0.79 CHRM1 (0.67) CHRM1CHRM4
Oxalic Acid SCHEMBL7619402 0.79 CHRM1 (0.71) CHRM1CHRM4
SCHEMBL6916467 0.76 CHRM1 (0.74) CHRM1CHRM4
SCHEMBL6913186 0.75 CHRM1 (0.87) CHRM1CHRM4SIGMAR1
Oxalic Acid SCHEMBL7474763 0.73 CHRM1 (0.63) CHRM1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP claimed
US-5753683-A SCHIZOPHRENIA NOVO NORDISK A/S (DK) 1998-05-19 US claimed
US-5744489-A ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS GREENWOOD BEVERLEY (US) 1998-04-28 US claimed
EP-0734259-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-10-02 EP claimed
EP-0687265-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-12-20 EP claimed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO claimed
WO-1994020495-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO claimed
US-20040023951-A1 Combination therapy for treatment of psychoses ELI LILLY AND COMPANY 2004-02-05 US disclosed
EP-0709094-B1 Tetrahydropyridine oxadiazole or thiadiazole compound for treating anxiety LILLY CO ELI (US) 2000-04-05 EP disclosed
US-5708014-A SUBSTITUTED TETRAHYDROPYRIDINYL-1,2,5-OXADIAZOLES OR THIADIAZOLES ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
WO-1996013167-A1 METHOD FOR TREATING ANXIETY ELI LILLY AND COMPANY (US) 1996-05-09 WO disclosed
EP-0709094-A2 Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound ELI LILLY AND COMPANY (US) 1996-05-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023951-A1 Combination therapy for treatment of psychoses CHRM5, CHRM4, CHRM2 CHRM1 8/4885CHRM4 2/4885SIGMAR1 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.